Raven Industries Debuts Driverless Ag Technology on Case IH Magnum™ at U.S. Farm Show
Raven Industries, Inc.(the Company; NASDAQ:RAVN), the leader in Driverless Ag Technology, announced today it will showcase and demonstrate the company’s OMNi suite of technology at Farm Progress Show, one of the largest public farm shows in the United States. At the show, Raven will feature its industry-leading technology in the event’s Autonomy Zone, where the company will debut OMNiDRIVE™ on Case IH Magnum™ and showcase OMNiPOWER™ performing autonomous missions. The public can experience OMNi August 31 through September 2, 2021, from 8:00 a.m. – 5:00 p.m. daily.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005184/en/
OMNiDRIVE™ by Raven is the first Driverless Ag Technology for grain cart harvest operations. (Photo: Business Wire)
Raven’s go-to-market strategy for OMNiDRIVE and dealer commitments for the technology are exceeding expectations. OMNiDRIVE was launched by Raven on May 12, 2021, with a year one limited release of 75 aftermarket systems. Today, all systems have been committed to by founding dealers. Through the remainder of the summer, the company is holding OMNiDRIVE demonstration events, where participants get a first-hand view of OMNiDRIVE controlling a driverless tractor pulling a grain cart and commanding it to sync with a harvester. Those interested in experiencing OMNiDRIVE and learning how the technology can dramatically impact their farm operations can sign up on ravenprecision.com/events.
OMNiDRIVE demonstrations this summer are being hosted by the company’s Founders Club members across the United States. Raven created the Founders Club, an elite group of dealers, to enhance the customer experience for ag professionals researching new driverless ag technology through OMNi’s first season of operation. The Founders Club involves intensive dealer training and demonstration requirements that help ag professionals think through a successful Path to Autonomy© for their operation.
“We recognize the challenges our farmers face daily,” said Jim Lilleberg, Director of Precision Ag and Machine Control for Titan Machinery, Inc. “Labor shortages, the need for efficiency improvements and scalability are all problems that OMNiDRIVE, now available for Case IH Magnum tractors, helps solve. We pride ourselves on being at the forefront of cutting-edge technology and the trusted partner to help enable it for our farmers. We feel this is the next major revolution in agriculture, and we are excited to be part of it!”
OMNiDRIVE™ is Raven’s aftermarket technology solution that transforms existing tractors into driverless machines. The technology connects, manages, and safely operates autonomous agricultural machinery and is compatible with:
- Case IH Magnum CVT (2014-2020 models): M250 / 280 / 310 / 340 / 380 (available in October 2021)
- New Holland CVT (2014-2020 models): T8.320 / 350 / 380 / 410 / 435 (available in October 2021)
- John Deere 8Rs Powershift and IVT (2010-current models)
OMNiPOWER™ is a self-propelled power platform that easily interchanges with farm implements, allowing the ag professional to perform multiple farming operations. OMNiPOWER is Raven’s premier platform that visually demonstrates the future of agriculture, drives innovation in the industry, and will accelerate the adoption of advanced autonomous solutions.
To learn more about what to expect from Raven at Farm Progress Show, visit ravenprecision.com/events/farm-progress-show.
About Raven Industries, Inc.
Raven Industries (NASDAQ: RAVN) provides innovative, high-value products and systems that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and aerospace and defense solutions, and the company’s groundbreaking work in autonomous systems is unlocking new possibilities in areas like farming, national defense, and scientific research. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, and unmatched service. For more information, visit https://ravenind.com/.
About Raven Applied Technology
For decades, Raven Applied Technology has been committed to maximizing operational efficiencies through its innovative agriculture technology. The company’s autonomous product suite, Raven Autonomy™, is an extension of that core. From field computers to sprayer and planter controls, GPS guidance steering systems, logistics technology, and autonomous solutions — Raven provides precision agriculture products designed for ag retailers and growers to remain competitive and profitable into the future. Learn more at https://ravenprecision.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005184/en/
Contact information
Erin Rinehart, Marketing Manager
Raven Industries
+1 (605) 809-2956
erin.rinehart@ravenind.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom